Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)

36Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

We provide detailed clinical, virological, and immunological data of a B-cell–depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.

Cite

CITATION STYLE

APA

Malsy, J., Veletzky, L., Heide, J., Hennigs, A., Gil-Ibanez, I., Stein, A., … zur Wiesch, J. S. (2021). Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 73(11), E4020–E4024. https://doi.org/10.1093/cid/ciaa1637

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free